Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607160 | 0.85 | MAPT (0.56) | MEN1KMT2AGRM1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4161919 | 0.84 | MEN1 (0.50) | MEN1KMT2AGRM1ESR1ESR2 | |
| SCHEMBL1616707 | 0.73 | MEN1 (0.63) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL26204969 | 0.73 | MEN1 (0.58) | MEN1KMT2AALDH1A1SMN1; SMN2MCHR1 | |
| SCHEMBL3755622 | 0.73 | MEN1 (0.58) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9953323 | 0.73 | RAB9A (0.76) | MEN1KMT2ASMN1; SMN2ESR1ESR2 | |
| SCHEMBL29377227 | 0.73 | RAB9A (0.76) | MEN1KMT2ASMN1; SMN2ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL30437013 | 0.71 | RAB9A (0.73) | MEN1KMT2ASMN1; SMN2ESR1ESR2 | |
| SCHEMBL2733196 | 0.70 | MEN1 (0.59) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL15939806 | 0.70 | GRM1 (1.00) | GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | MEN1 2927/4885KMT2A 905/4885GRM1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.